Lite Strategy Inc (LITS)

• Market cap: $69.5M
• 1 day: -1.52%
• 5 days: -12.95%
• 1 month: -24.42%
• 3 months: -70.23%
• 6 months: 2.09%
• Year to date: -23.53%
• 1 year: -28.83%
• 5 years: -96.4%
• 10 years: -94.55%
• Sector: Healthcare
• Industry: Biotechnology

About: Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Employees: 4